Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.
OBJECTIVE
This study was undertaken to assess the pharmacodynamic profile, safety, and efficacy of tinzaparin during pregnancy.


METHODS
Fifty-four pregnant women, 12 for treatment of thrombosis and 42 for thromboprophylaxis, received tinzaparin by once daily injection. Four-hour postdose anti-Xa results were analyzed by use of repeated measures statistical methods.


RESULTS
One woman (3.4%) on the 175 anti-Xa U/kg dose and three women (20%) on the 50 anti-Xa U/kg dose required a dose increase during the initial dose titration phase to achieve target anti-Xa activity. No thrombotic events occurred.


CONCLUSIONS
The 175 anti-Xa U/kg dose is appropriate for treatment and for high-risk thromboprophylaxis throughout pregnancy. In pregnant women at moderate risk of thrombosis, a higher tinzaparin dose is required than in the nonpregnant state and 75 anti-Xa U/kg appears to be appropriate. The majority of women do not need a dose increase with advancing gestation.
Reference Centre for Haemostatic and Thrombotic Disorders, St Thomas' Hospital, Dublin, Ireland. mark.smith@cdhb.govt.nz
Mark P
MP
Smith
Lucy A
LA
Norris
Philip J
PJ
Steer
Geoffrey F
GF
Savidge
John
J
Bonnar
D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D005865:Gestational Age; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000517:prevention & control; D011256:Pregnancy Outcome; D011446:Prospective Studies; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin